{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:02:45Z","timestamp":1771678965755,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","award":["R01HL113508"],"award-info":[{"award-number":["R01HL113508"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sarcoidosis is a systemic granulomatous disease of unknown etiology with significant heterogeneity in organ manifestations and clinical course. Subjects with sarcoidosis share several features such as, non-necrotizing granuloma, hypergammaglobulinemia, increased local and circulating inflammatory cytokines. Macrophage migration inhibitory factor (MIF) is a pluripotent chemokine modulating cellular function. Study included healthy controls (n\u2009=\u200928) and sarcoidosis patients (n\u2009=\u200965). Sera and BAL of sarcoidosis patients were collected and patients were followed longitudinally for 3\u00a0years, and demographics, stages, pulmonary function tests, and organ involvements were recorded. We evaluated MIF in the serum and bronchoalveolar lavage (BAL) fluid of sarcoidosis patients in association with clinical features and cytokines, IL-18, IL-10, IL-6, IFN-\u03b3. We found serum MIF had a positive correlation with IL-10 and IFN-\u03b3 and % predicted total lung capacity (%TLC). Serum IL-18 had a significant positive correlation with serum lysozyme, but a negative correlation with %TLC and %DLCO. We identified two groups of sarcoidosis subjects with distinct clinical and cytokine features. A group with prominent extrapulmonary involvement, and low serum MIF, IL-10 and IFN-\u03b3 and a group with elevated serum MIF, IL-10 and IFN-\u03b3 levels. Our work provides understanding of phenotypic diversity in association with heterogeneity in cytokine landscape in sarcoidosis.<\/jats:p>","DOI":"10.1038\/s41598-022-21212-5","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:07:04Z","timestamp":1665162424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modulatory role of macrophage migration inhibitory factor on cytokines and clinical features of sarcoidosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Morvarid","family":"Elahi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Talreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennen","family":"Steinbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Koth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lobelia","family":"Samavati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"21212_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01273","author":"L Farr","year":"2020","unstructured":"Farr, L., Ghosh, S. & Moonah, S. Role of MIF cytokine\/CD74 receptor pathway in protecting against injury and promoting repair. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.01273 (2020).","journal-title":"Front. Immunol."},{"key":"21212_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.drudis.2018.11.003","volume":"24","author":"S G\u00fcnther","year":"2019","unstructured":"G\u00fcnther, S. et al. Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: From pathogenic factors to therapeutic targets. Drug Discov. Today 24, 428\u2013439 (2019).","journal-title":"Drug Discov. Today"},{"key":"21212_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1681\/ASN.2008020194","volume":"20","author":"MD Sanchez-Ni\u00f1o","year":"2009","unstructured":"Sanchez-Ni\u00f1o, M. D. et al. The MIF receptor CD74 in diabetic podocyte injury. J. Am. Soc. Nephrol. 20, 353\u2013362 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"21212_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/jmbi.1998.1864","volume":"280","author":"R Kleemann","year":"1998","unstructured":"Kleemann, R. et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J. Mol. Biol. 280, 85\u2013102 (1998).","journal-title":"J. Mol. Biol."},{"key":"21212_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fimmu.2013.00115","volume":"4","author":"S Tillmann","year":"2013","unstructured":"Tillmann, S., Bernhagen, J. D. & Noels, H. Arrest functions of the MIF ligand\/receptor axes in atherogenesis. Front. Immunol. 4, 115 (2013).","journal-title":"Front. Immunol."},{"key":"21212_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122482","volume":"10","author":"G Ningyan","year":"2015","unstructured":"Ningyan, G., Xu, Y., Hongfei, S., Jingjing, C. & Min, C. The role of macrophage migration inhibitory factor in mast cell-stimulated fibroblast proliferation and collagen production. PLoS ONE 10, e0122482 (2015).","journal-title":"PLoS ONE"},{"key":"21212_CR7","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1073\/pnas.212488699","volume":"99","author":"H Koebernick","year":"2002","unstructured":"Koebernick, H. et al. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc. Natl. Acad. Sci. 99, 13681\u201313686 (2002).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"21212_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan4886","author":"C Stoppe","year":"2018","unstructured":"Stoppe, C. et al. The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan4886 (2018).","journal-title":"Sci. Transl. Med."},{"key":"21212_CR9","doi-asserted-by":"publisher","first-page":"E997","DOI":"10.1073\/pnas.1514018113","volume":"113","author":"T Roger","year":"2016","unstructured":"Roger, T. et al. High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. Proc. Natl. Acad. Sci. 113, E997\u2013E1005 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"21212_CR10","doi-asserted-by":"publisher","first-page":"E2997","DOI":"10.1073\/pnas.1301128110","volume":"110","author":"R Das","year":"2013","unstructured":"Das, R. et al. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 110, E2997\u2013E3006 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"21212_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1164\/rccm.201005-0792OC","volume":"183","author":"R Rastogi","year":"2011","unstructured":"Rastogi, R. et al. Dysregulation of p38 and MKP-1 in response to NOD1\/TLR4 stimulation in sarcoid bronchoalveolar cells. Am. J. Respir. Crit. Care Med. 183, 500\u2013510. https:\/\/doi.org\/10.1164\/rccm.201005-0792OC (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"21212_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.4049\/jimmunol.1600258","volume":"197","author":"J Talreja","year":"2016","unstructured":"Talreja, J., Talwar, H., Ahmad, N., Rastogi, R. & Samavati, L. Dual inhibition of Rip2 and IRAK1\/4 regulates IL-1beta and IL-6 in sarcoidosis alveolar macrophages and peripheral blood mononuclear cells. J. Immunol. 197, 1368\u20131378. https:\/\/doi.org\/10.4049\/jimmunol.1600258 (2016).","journal-title":"J. Immunol."},{"key":"21212_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44519","author":"J Talreja","year":"2019","unstructured":"Talreja, J. et al. HIF-1alpha regulates IL-1beta and IL-17 in sarcoidosis. Elife https:\/\/doi.org\/10.7554\/eLife.44519 (2019).","journal-title":"Elife"},{"key":"21212_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/827254","author":"GJ Tob\u00f3n","year":"2019","unstructured":"Tob\u00f3n, G. J., Izquierdo, J. H. & Ca\u00f1as, C. A. B lymphocytes: development, tolerance, and their role in autoimmunity\u2014focus on systemic lupus erythematosus. Autoimmune Dis. 2013, 1\u201317. https:\/\/doi.org\/10.1155\/2013\/827254 (2013).","journal-title":"Autoimmune Dis."},{"key":"21212_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nri1200","volume":"3","author":"T Calandra","year":"2003","unstructured":"Calandra, T. & Roger, T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat. Rev. Immunol. 3, 791\u2013800 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"21212_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1034\/j.1399-3003.1999.14d02.x","volume":"14","author":"U Costabel","year":"1999","unstructured":"Costabel, U. & Hunninghake, G. W. ATS\/ERS\/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American thoracic society. European respiratory society. World association for sarcoidosis and other granulomatous disorders. Eur. Respir. J. 14, 735\u2013737 (1999).","journal-title":"Eur. Respir. J."},{"key":"21212_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1183\/09031936.00175907","volume":"32","author":"JM Bourbonnais","year":"2008","unstructured":"Bourbonnais, J. M. & Samavati, L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur. Respir. J. 32, 296\u2013302. https:\/\/doi.org\/10.1183\/09031936.00175907 (2008).","journal-title":"Eur. Respir. J."},{"key":"21212_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","volume":"196","author":"BH Culver","year":"2017","unstructured":"Culver, B. H. et al. Recommendations for a standardized pulmonary function report. An official American thoracic society technical statement. Am. J. Respir. Crit. Care Med. 196, 1463\u20131472 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"21212_CR19","first-page":"38","volume":"23","author":"MP Bihl","year":"2006","unstructured":"Bihl, M. P. et al. Progressive pulmonary sarcoidosis\u2013a fibroproliferative process potentially triggered by EGR-1 and IL-6. Sarcoidosis Vasc. Diffuse Lung Dis. Off. J. WASOG 23, 38\u201350 (2006).","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis. Off. J. WASOG"},{"key":"21212_CR20","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1164\/ajrccm.162.5.9911113","volume":"162","author":"K Shigehara","year":"2000","unstructured":"Shigehara, K. et al. Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 162, 1979\u20131982 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"21212_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.rmed.2006.08.019","volume":"101","author":"R Kieszko","year":"2007","unstructured":"Kieszko, R. et al. The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respir. Med. 101, 722\u2013728 (2007).","journal-title":"Respir. Med."},{"key":"21212_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193122","volume":"13","author":"N Belhomme","year":"2018","unstructured":"Belhomme, N. et al. Role of serum immunoglobulins for predicting sarcoidosis outcome: A cohort study. PLoS ONE 13, e0193122 (2018).","journal-title":"PLoS ONE"},{"key":"21212_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1164\/ajrccm\/143.1.53","volume":"143","author":"C Prior","year":"1991","unstructured":"Prior, C. & Haslam, P. L. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am. Rev. Respir. Dis. 143, 53\u201360 (1991).","journal-title":"Am. Rev. Respir. Dis."},{"key":"21212_CR24","doi-asserted-by":"crossref","unstructured":"Iyer, S. S. & Cheng, G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev.\u2122 Immunol. 32, 23\u201363 (2012).","DOI":"10.1615\/CritRevImmunol.v32.i1.30"},{"key":"21212_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/PL00007637","volume":"177","author":"H Tomita","year":"1999","unstructured":"Tomita, H. et al. Serum lysozyme levels and clinical features of sarcoidosis. Lung 177, 161\u2013167 (1999).","journal-title":"Lung"},{"key":"21212_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1378\/chest.09-1975","volume":"137","author":"S Miyoshi","year":"2010","unstructured":"Miyoshi, S. et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 137, 1391\u20131397 (2010).","journal-title":"Chest"},{"key":"21212_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.174.5.1049","volume":"174","author":"S Keshav","year":"1991","unstructured":"Keshav, S., Chung, P., Milon, G. & Gordon, S. Lysozyme is an inducible marker of macrophage activation in murine tissues as demonstrated by in situ hybridization. J. Exp. Med. 174, 1049\u20131058 (1991).","journal-title":"J. Exp. Med."},{"key":"21212_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","volume":"6","author":"P Spagnolo","year":"2018","unstructured":"Spagnolo, P. et al. Pulmonary sarcoidosis. Lancet Respir. Med. 6, 389\u2013402 (2018).","journal-title":"Lancet Respir. Med."},{"key":"21212_CR29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1183\/09031936.98.12030716","volume":"12","author":"J Muller-Quernheim","year":"1998","unstructured":"Muller-Quernheim, J. Sarcoidosis: Immunopathogenetic concepts and their clinical application. Eur. Respir. J. 12, 716\u2013738 (1998).","journal-title":"Eur. Respir. J."},{"key":"21212_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccm.2008.03.007","volume":"29","author":"J Muller-Quernheim","year":"2008","unstructured":"Muller-Quernheim, J. et al. Genetics of sarcoidosis. Clin. Chest Med. 29, 391\u2013414. https:\/\/doi.org\/10.1016\/j.ccm.2008.03.007 (2008).","journal-title":"Clin. Chest Med."},{"key":"21212_CR31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.3389\/fimmu.2019.02375","volume":"10","author":"KJ Filbey","year":"2019","unstructured":"Filbey, K. J. et al. Macrophage migration inhibitory factor (MIF) is essential for type 2 effector cell immunity to an intestinal helminth parasite. Front. Immunol. 10, 2375 (2019).","journal-title":"Front. Immunol."},{"key":"21212_CR32","doi-asserted-by":"publisher","first-page":"L1183","DOI":"10.1152\/ajplung.00521.2019","volume":"318","author":"L Florez-Sampedro","year":"2020","unstructured":"Florez-Sampedro, L., Soto-Gamez, A., Poelarends, G. J. & Melgert, B. N. The role of MIF in chronic lung diseases: Looking beyond inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 318, L1183\u2013L1197 (2020).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"21212_CR33","doi-asserted-by":"publisher","first-page":"L442","DOI":"10.1152\/ajplung.00525.2007","volume":"296","author":"LM Marsh","year":"2009","unstructured":"Marsh, L. M. et al. Surface expression of CD74 by type II alveolar epithelial cells: A potential mechanism for macrophage migration inhibitory factor-induced epithelial repair. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L442\u2013L452 (2009).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"21212_CR34","volume-title":"D-Dopachrome Tautomerase Contributes to Lung Epithelial Repair Via Atypical Chemokine Receptor 3-Dependent Akt Signaling","author":"H Habibie","year":"2021","unstructured":"Habibie, H. D-Dopachrome Tautomerase Contributes to Lung Epithelial Repair Via Atypical Chemokine Receptor 3-Dependent Akt Signaling (Elsevier, 2021)."},{"key":"21212_CR35","doi-asserted-by":"crossref","unstructured":"Lin, F.-C. & Young, H. A. The talented interferon-gamma. (2013).","DOI":"10.4236\/abb.2013.47A3002"},{"key":"21212_CR36","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat, F. J., Crow, M. K. & Ivashkiv, L. B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 20, 1574\u20131583. https:\/\/doi.org\/10.1038\/s41590-019-0466-2 (2019).","journal-title":"Nat. Immunol."},{"key":"21212_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9101762","author":"J de Dios Ruiz-Rosado","year":"2016","unstructured":"de Dios Ruiz-Rosado, J. et al. MIF promotes classical activation and conversion of inflammatory Ly6Chigh monocytes into TipDCs during murine toxoplasmosis. Mediat. Inflamm. https:\/\/doi.org\/10.1155\/2016\/9101762 (2016).","journal-title":"Mediat. Inflamm."},{"key":"21212_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2567.2008.02986.x","volume":"127","author":"Y Yanagawa","year":"2009","unstructured":"Yanagawa, Y., Iwabuchi, K. & Ono\u00e9, K. Co-operative action of interleukin-10 and interferon-\u03b3 to regulate dendritic cell functions. Immunology 127, 345\u2013353 (2009).","journal-title":"Immunology"},{"key":"21212_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.it.2006.02.008","volume":"27","author":"KJ Wood","year":"2006","unstructured":"Wood, K. J. & Sawitzki, B. Interferon \u03b3: A crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 27, 183\u2013187 (2006).","journal-title":"Trends Immunol."},{"key":"21212_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155372","volume":"138","author":"D Gajic","year":"2021","unstructured":"Gajic, D., Koprivica, I., Stojanovic, I. & Saksida, T. Defective immunosuppressive function of Treg cells in visceral adipose tissue in MIF deficient mice. Cytokine 138, 155372 (2021).","journal-title":"Cytokine"},{"key":"21212_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20050648","volume":"203","author":"M Miyara","year":"2006","unstructured":"Miyara, M. et al. The immune paradox of sarcoidosis and regulatory T cells. J. Exp. Med. 203, 359\u2013370. https:\/\/doi.org\/10.1084\/jem.20050648 (2006).","journal-title":"J. Exp. Med."},{"key":"21212_CR42","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2006-03-005595","volume":"108","author":"C Qian","year":"2006","unstructured":"Qian, C. et al. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 108, 2307\u20132315 (2006).","journal-title":"Blood"},{"key":"21212_CR43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1165\/rcmb.2014-0403OC","volume":"54","author":"J Fallica","year":"2016","unstructured":"Fallica, J. et al. Macrophage migration inhibitory factor: A novel inhibitor of apoptosis signal-regulating kinase 1\u2013p38\u2013xanthine oxidoreductase-dependent cigarette smoke-induced apoptosis. Am. J. Respir. Cell Mol. Biol. 54, 504\u2013514 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"21212_CR44","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1152\/ajplung.00339.2014","volume":"309","author":"M Sauler","year":"2015","unstructured":"Sauler, M., Bucala, R. & Lee, P. J. Role of macrophage migration inhibitory factor in age-related lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L1\u2013L10 (2015).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"21212_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","volume":"4","author":"CA Dinarello","year":"2013","unstructured":"Dinarello, C. A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 4, 289 (2013).","journal-title":"Front. Immunol."},{"key":"21212_CR46","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.4049\/jimmunol.165.8.4718","volume":"165","author":"CM Greene","year":"2000","unstructured":"Greene, C. M. et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J. Immunol. 165, 4718\u20134724 (2000).","journal-title":"J. Immunol."},{"key":"21212_CR47","first-page":"507","volume":"59","author":"R Mroz","year":"2008","unstructured":"Mroz, R., Korniluk, M., Stasiak-Barmuta, A. & Chyczewska, E. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J. Physiol. Pharmacol. 59, 507\u2013513 (2008).","journal-title":"J. Physiol. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21212-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:13:18Z","timestamp":1665162798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21212-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21212"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21212-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16906"}}